<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31772">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887418</url>
  </required_header>
  <id_info>
    <org_study_id>QST 13002</org_study_id>
    <nct_id>NCT01887418</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Testosterone Enanthate</brief_title>
  <official_title>3 Arm, Open-label, Randomized, Multidose Parallel Group Study of Pharmacokinetics, Safety, and Tolerability of Two Dose Levels of a Formulation of Testosterone Enanthate in a Device or Needle and Syringe in Hypogonadal Adult Male</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antares Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antares Pharma Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relative bioavailability and safety comparison of 3 formulations of testosterone enanthate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard pharmacokinetic analyses of blood concentration data for serum testosterone,
      dihydrotestosterone and estradiol comparing, Cmax, area under the concentration time curve,
      and average blood concentration to facilitate the comparison of the relative bioavailability
      of the treatment and control arms.  Safety comparisons will be based upon the occurrence,
      severity and rate of treatment emergent adverse events and measurement of standard safety
      laboratory parameters, as well as assessment of the frequency and severity of any
      derangements of laboratory parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Relative bioavailability of testosterone enanthate formulations</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>7 or 14 days of blood sampling following dosing to determine the average concentration, maximum observed plasma concentration (Cmax), area under the curve from time zero to last quantifiable concentration [AUC (0-t)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Collection of overall treatment emergent adverse events, and determination of frequency of TEAE for each system organ class, in order to determine whether a pattern(s) is present.
Collections of routine labs and prostate specific antigen to determine whether there are laboratory abnormalities associated with study drug admininstration.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Combination A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QuickShot™ and testosterone enanthate- combination A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QuickShot™ and testosterone enanthate- combination B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delatestryl/needle/syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially obtained Testosterone enanthate 200 mg dose standard of care arm for reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QuickShot™ and testosterone enanthate- combination B</intervention_name>
    <description>QuickShot™ for the delivery of testosterone</description>
    <arm_group_label>Combination B</arm_group_label>
    <other_name>Testosterone, testosterone enanthate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QuickShot™ and testosterone enanthate- combination A</intervention_name>
    <description>QuickShot™ for the delivery of testosterone</description>
    <arm_group_label>Combination A</arm_group_label>
    <other_name>testosterone, testosterone enanthate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delatestryl/needle/syringe</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Delatestryl/needle/syringe</arm_group_label>
    <other_name>testosterone, testosterone enanthate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males aged 18 to 75 with a documented diagnosis of hypogonadism

        Exclusion Criteria:

          -  Normal testosterone levels

          -  Subjects with any clinically significant medical condition which, in the opinion of
             the Investigator, would make the subject an unsuitable candidate for enrollment in
             the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Bedel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prestige Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mens Health Boston</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Testosterone enanthate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
